惠泰医疗(688617) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 reached ¥523,869,294.35, representing a year-on-year increase of 23.05%[2] - Net profit attributable to shareholders was ¥185,586,095.90, reflecting a growth of 27.24% compared to the same period last year[2] - The basic earnings per share (EPS) for the period was ¥1.91, an increase of 27.33% year-on-year[4] - The net profit excluding non-recurring gains and losses for the year-to-date was ¥180,393,121.65, up 53.15% from the previous year[8] - The net profit attributable to shareholders for the year-to-date increased by 30.97% compared to the previous year[7] - In the first three quarters of 2024, the net profit reached CNY 522,050,612.64, an increase of 31.6% compared to CNY 396,563,367.77 in the same period of 2023[18] - The operating profit for the first three quarters of 2024 was CNY 589,309,852.67, up from CNY 455,012,658.28 in 2023, reflecting a growth of 29.5%[18] - The total comprehensive income for the first three quarters of 2024 was CNY 532,643,770.84, compared to CNY 410,753,518.73 in 2023, an increase of 29.7%[19] Assets and Liabilities - Total assets as of the end of the reporting period were ¥2,803,921,171.32, an increase of 8.98% from the end of the previous year[4] - The company's total assets as of September 30, 2024, amounted to CNY 2,803,921,171.32, up from CNY 2,572,982,295.44 at the end of 2023, reflecting a growth of approximately 8.9%[16] - The company's total liabilities decreased to CNY 367,807,271.76 from CNY 610,981,432.09, a reduction of approximately 39.9%[16] - The equity attributable to shareholders reached CNY 2,388,153,365.00 as of September 30, 2024, compared to CNY 1,907,142,308.67 at the end of 2023, representing an increase of about 25.2%[16] Cash Flow - The company's cash and cash equivalents as of September 30, 2024, were approximately ¥599.61 million, down from ¥1.28 billion at the end of 2023[13] - The net cash flow from operating activities for the first three quarters of 2024 was ¥523,837,422.35, an increase from ¥484,558,878.95 in the same period of 2023, representing a growth of approximately 8.5%[21] - Total cash inflow from investment activities was ¥362,194,716.19, significantly lower than ¥1,198,081,615.15 in the previous year, indicating a decline of about 69.7%[21] - The net cash flow from investment activities was -¥877,740,822.75, compared to -¥47,913,952.10 in the same period of 2023, reflecting a substantial increase in cash outflow[21] - Cash flow from financing activities resulted in a net outflow of -¥320,399,560.82, worsening from -¥238,959,527.67 in the previous year[22] - The total cash and cash equivalents at the end of the period stood at ¥599,613,654.94, down from ¥451,530,046.17 in the same period last year, indicating a decrease of approximately 32.8%[22] Shareholder Information - The total number of common shareholders at the end of the reporting period was 3,995[9] - The largest shareholder, Shenzhen Mindray Technology Co., Ltd., holds 20,474,450 shares, accounting for 21.04% of the total shares[10] - The second-largest shareholder, Cheng Zhenghui, holds 18,153,056 shares, representing 18.65% of the total shares[10] - The top ten shareholders include various investment funds, with the largest fund holding 4,064,287 shares, or 4.18%[10] - There are no significant changes in the shareholding structure due to margin trading activities during the reporting period[12] Research and Development - Research and development (R&D) expenses totaled ¥68,962,644.09, accounting for 13.16% of operating revenue, a decrease of 0.79 percentage points from the previous year[4] - Research and development expenses increased to CNY 202,856,157.35 in 2024 from CNY 168,316,723.06 in 2023, marking a rise of 20.5%[18] Operational Updates - The company has not reported any new strategies or significant operational changes in the current quarter[13] - The report does not indicate any ongoing or planned mergers or acquisitions[13] - There are no new product launches or technological developments mentioned in the current report[13] - The company has not provided specific future guidance or performance outlook in the current report[13] Revenue and Costs - Total operating revenue for the first three quarters of 2024 reached CNY 1,524,828,925.89, an increase from CNY 1,213,709,560.43 in the same period of 2023, representing a growth of approximately 25.6%[17] - Total operating costs for the first three quarters of 2024 were CNY 970,562,004.58, compared to CNY 822,000,174.52 in 2023, indicating an increase of about 18.1%[17] - Total revenue for the first three quarters of 2024 was CNY 1,664,312,497.91, compared to CNY 1,338,983,063.61 in 2023, indicating a growth of 24.3%[20] Employee Compensation - The company paid cash for employee compensation amounting to ¥424,613,716.97, which is an increase from ¥328,541,327.58 in the same period of 2023, reflecting a growth of about 29.2%[21]